Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation
The company has received five final approvals
AMP-6 & AMP-8 are special purpose entities formed for purpose of setting up captive solar power projects in Karnataka
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
The company received gross proceeds of approximately US$1.7 million and net proceeds,
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
AMI to become part of Enpro’s Sealing Technologies Segment
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Subscribe To Our Newsletter & Stay Updated
